General
Preferred name
FLUOROURACIL
Synonyms
5-fluorouracil ()
5-FU ()
NSC 19893 ()
5-Fluoracil ()
Fluorouracil (Adrucil) ()
Efudex ()
Adrucil ()
5-Fluoro-2,4-pyrimidinedione ()
5-Fluoropyrimidine-2,4-dione ()
5-Fluoro-2,4(1H,3H)-pyrimidinedione ()
Uracil, 5-fluoro- ()
Effluderm (free base) ()
Fluorouracil (5-Fluorouracil, 5-FU) ()
NSC 19893,5-Fluorouracil, 5-FU ()
RO 2-9757 ()
Ro-29757 ()
Queroplex ()
RO-2-9757 ()
Carac ()
Fluoro-Uracil Roche ()
Tolak ()
NSC-19893 ()
5 FU ()
Fluoroplex ()
Efudix ()
Fluorouricil ()
Actikerall ()
Fluracil ()
Accusite ()
5-Fluorouracil ()
Fluorouracilum ()
5-fluoruracil ()
Fluorouracilo ()
Phthoruracil ()
5.F.U. ()
5-Fluorouracil-13C,15N2 ()
P&D ID
PD002327
CAS
51-21-8
1004-03-1
1189423-58-2
Tags
available
drug
Approved by
FDA
PMDA
First approval
1962
Drug indication
Colorectal cancer
Solid tumour/cancer
Antineoplastic
Tumour
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Seven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour.; The remaining percentage of the administered dose is metabolized, primarily in the liver.
DESCRIPTION Fluoroacil is the active metabolite of the prodrugs and . (GtoPdb)
DESCRIPTION pyrimidine analog; inhibitor of thymidylate synthase (Informer Set)
DESCRIPTION Selective, reversible FAAH inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Thymidylate synthetase inhibitor; leads to accumulation of cells in S phase (LOPAC library)
Cell lines
211
Organisms
6
Compound Sets
39
AdooQ Bioactive Compound Library
A10042
Cayman Chemical Bioactives
14416
26683
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL185
ChEMBL Drugs
CHEMBL185
Concise Guide to Pharmacology 2017/18
4789
Concise Guide to Pharmacology 2019/20
4789
Concise Guide to Pharmacology 2021/22
4789
Concise Guide to Pharmacology 2023/24
4789
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00544
DrugBank Approved Drugs
DB00544
DrugCentral
26
DrugCentral Approved Drugs
26
DrugMAP
DMUM7HZ
DrugMAP Approved Drugs
DMUM7HZ
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101699
Guide to Pharmacology
4789
Informer Set
25344
LINCS compound set
10238-101
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL185
Mcule NIBR MoA Box Subset
MCULE-6338086431
MedChem Express Bioactive Compound Library
HY-90006
NCATS Inxight Approved Drugs
U3P01618RT
NIH Approved Oncology Drugs
82653
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Adrucil(Fluorouracil)
TargetMol Bioactive Compound Library
T0984
The Spectrum Collection
Tocris Bioactive Compound Library
3257
Welcome Trust Cancer Drugs
179
External IDs
63
Properties
(calculated by RDKit )
Molecular Weight
130.02
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
0
Ring Count
1
Aromatic Ring Count
1
cLogP
-0.8
TPSA
65.72
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
TYMS
DNA antimetabolite
Thymidylate Synthase
DNA
RNA
DPYD, TYMS
Endogenous Metabolite
HIV
Nucleoside antimetabolite/analog
Apoptosis related,DNA/RNA Synthesis,HIV,Nucleoside Analog/Antimetabolite,Thymidylate Synthase
Compound status
FDA
Pathway
DNA replication
DNA Damage/DNA Repair
Anti-infection
Apoptosis
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Selectivity
Thymidylate synthetase
MOA
Thymidylate synthase inhibitor
DNA/RNA Synthesis
Inhibitor
thymidylate synthase
Primary Target
Thymidylate Synthetase
Member status
member
Indication
colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma
Therapeutic Class
Immunosuppressive Agents
Source data